Attention-Deficit/Hyperactivity Disorder Archives - MPR

Attention-Deficit/Hyperactivity Disorder

Viloxazine NDA Submitted for Review as Potential New ADHD Treatment

The New Drug Application (NDA) for viloxazine hydrochloride (SPN-812; Supernus Pharmaceuticals), a serotonin norepinephrine modulating agent, has been submitted to the Food and Drug Administration (FDA) for the treatment of pediatric patients with attention deficit hyperactivity disorder (ADHD). The submission is supported by data from an extensive development program that included four phase 3 studies…

Concomitant Stimulant, Quinolone Use May Increase Risk of Cardiac Symptoms

There appears to be an increased risk of cardiac symptoms, but not cardiac arrhythmias, in patients using stimulants and quinolone antibiotics concomitantly compared with those taking stimulants plus amoxicillin or azithromycin, according to the findings of a recently published retrospective cohort study.   In the study, MarketScan claims data (between 2008 and 2015) of privately-insured patients…